PE Tech Report


Like this article?

Sign up to our free newsletter

Audax Private Equity acquires Altasciences Clinical Research

Audax Private Equity has partnered with management to acquire Altasciences Company, an early phase contract research organisation (CRO) in North America.

Audax acquired Altasciences from Kilmer Capital Partners, a private equity firm based in Toronto, Canada. Terms of the transaction have not been disclosed.
Altasciences, headquartered in Laval, Quebec, encompasses Algorithme Pharma, Vince & Associates Clinical Research, and Algorithme Pharma USA. Altasciences offers expertise in the execution of a wide range of New Drug Application (NDA) enabling clinical trials and support services including data management, biostatistics, medical writing, and bioanalysis.
Geoffrey S Rehnert, Co-Chief Executive Officer, Audax Group, says: “Altasciences is a leader in the early phase clinical research industry. We look forward to working with Chris Perkin and the Altasciences team to continue building a leading platform through organic growth and add-on acquisitions.”
Chris Perkin, Chief Executive Officer, Altasciences, says: “We are excited to be partnering with Audax for the next stage of our growth. Audax brings expertise and resources that will help us continue to build our market leadership position by expanding our service offering and value proposition to our clients through strategic acquisitions and growth initiatives.”
Fairmount Partners served as financial advisor to Altasciences. Blake, Cassels & Graydon, LLP and Kirkland & Ellis, LLP served as counsel to Audax.

Like this article? Sign up to our free newsletter